Literature DB >> 28033443

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.

Guido Neidhardt1,2, Jan Hauke1,2, Juliane Ramser3, Eva Groß3, Andrea Gehrig4, Clemens R Müller4, Anne-Karin Kahlert5,6, Karl Hackmann5, Ellen Honisch7, Dieter Niederacher7, Stefanie Heilmann-Heimbach8,9, André Franke10, Wolfgang Lieb11, Holger Thiele12, Janine Altmüller12,13, Peter Nürnberg2,12,14, Kristina Klaschik1,2, Corinna Ernst1, Nina Ditsch15, Frank Jessen16,17, Alfredo Ramirez8,17,18, Barbara Wappenschmidt1,2, Christoph Engel19, Kerstin Rhiem1,2, Alfons Meindl3, Rita K Schmutzler1,2, Eric Hahnen1,2.   

Abstract

IMPORTANCE: Germline mutations in established moderately or highly penetrant risk genes for breast cancer (BC) and/or ovarian cancer (OC), including BRCA1 and BRCA2, explain fewer than half of all familial BC and/or OC cases. Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a novel BC predisposition gene, while the analysis of the entire coding region of the FANCM gene in familial index cases and geographically matched controls is pending.
OBJECTIVES: To assess the mutational spectrum within the FANCM gene, and to determine a potential association of LoF germline mutations within the FANCM gene with BC and/or OC risk. DESIGN, SETTING, AND PARTICIPANTS: For the purpose of identification and characterization of novel BC and/or OC predisposition genes, a total of 2047 well-characterized familial BC index cases, 628 OC cases, and 2187 geographically matched controls were screened for LoF mutations within the FANCM gene by next-generation sequencing. All patients previously tested negative for pathogenic BRCA1 and BRCA2 mutations. All data collection occurred between June 1, 2013, and April 30, 2016. Data analysis was performed from May 1, 2016, to July 1, 2016. MAIN OUTCOMES AND MEASURES: FANCM LoF mutation frequencies in patients with BC and/or OC were compared with the FANCM LoF mutation frequencies in geographically matched controls by univariate logistic regression. Positive associations were stratified by age at onset and cancer family history.
RESULTS: In this case-control study, 2047 well-characterized familial female BC index cases, 628 OC cases, and 2187 geographically matched controls were screened for truncating FANCM alterations. Heterozygous LoF mutations within the FANCM gene were significantly associated with familial BC risk, with an overall odds ratio (OR) of 2.05 (95% CI, 0.94-4.54; P = .049) and a mutation frequency of 1.03% in index cases. In familial patients whose BC onset was before age 51 years, an elevated OR of 2.44 (95% CI, 1.08-5.59; P = .02) was observed. A more pronounced association was identified for patients with a triple-negative BC tumor phenotype (OR, 3.75; 95% CI, 1.00-12.85; P = .02). No significant association was detected for unselected OC cases (OR, 1.74; 95% CI, 0.57-5.08; P = .27). CONCLUSIONS AND RELEVANCE: Based on the significant associations of heterozygous LoF mutations with early-onset or triple-negative BC, FANCM should be included in diagnostic gene panel testing for individual risk assessment. Larger studies are required to determine age-dependent disease risks for BC and to assess a potential role of FANCM mutations in OC pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28033443      PMCID: PMC5824291          DOI: 10.1001/jamaoncol.2016.5592

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  8 in total

1.  Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.

Authors:  Alberto Ciccia; Chen Ling; Rachel Coulthard; Zhijiang Yan; Yutong Xue; Amom Ruhikanta Meetei; El Houari Laghmani; Hans Joenje; Neil McDonald; Johan P de Winter; Weidong Wang; Stephen C West
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

2.  FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Authors:  Paolo Peterlongo; Irene Catucci; Mara Colombo; Laura Caleca; Eliseos Mucaki; Massimo Bogliolo; Maria Marin; Francesca Damiola; Loris Bernard; Valeria Pensotti; Sara Volorio; Valentina Dall'Olio; Alfons Meindl; Claus Bartram; Christian Sutter; Harald Surowy; Valérie Sornin; Marie-Gabrielle Dondon; Séverine Eon-Marchais; Dominique Stoppa-Lyonnet; Nadine Andrieu; Olga M Sinilnikova; Gillian Mitchell; Paul A James; Ella Thompson; Marina Marchetti; Cristina Verzeroli; Carmen Tartari; Gabriele Lorenzo Capone; Anna Laura Putignano; Maurizio Genuardi; Veronica Medici; Isabella Marchi; Massimo Federico; Silvia Tognazzo; Laura Matricardi; Simona Agata; Riccardo Dolcetti; Lara Della Puppa; Giulia Cini; Viviana Gismondi; Valeria Viassolo; Chiara Perfumo; Maria Antonietta Mencarelli; Margherita Baldassarri; Bernard Peissel; Gaia Roversi; Valentina Silvestri; Piera Rizzolo; Francesca Spina; Caterina Vivanet; Maria Grazia Tibiletti; Maria Adelaide Caligo; Gaetana Gambino; Stefania Tommasi; Brunella Pilato; Carlo Tondini; Chiara Corna; Bernardo Bonanni; Monica Barile; Ana Osorio; Javier Benitez; Luisa Balestrino; Laura Ottini; Siranoush Manoukian; Marco A Pierotti; Alessandra Renieri; Liliana Varesco; Fergus J Couch; Xianshu Wang; Peter Devilee; Florentine S Hilbers; Christi J van Asperen; Alessandra Viel; Marco Montagna; Laura Cortesi; Orland Diez; Judith Balmaña; Jan Hauke; Rita K Schmutzler; Laura Papi; Miguel Angel Pujana; Conxi Lázaro; Anna Falanga; Kenneth Offit; Joseph Vijai; Ian Campbell; Barbara Burwinkel; Anders Kvist; Hans Ehrencrona; Sylvie Mazoyer; Sara Pizzamiglio; Paolo Verderio; Jordi Surralles; Peter K Rogan; Paolo Radice
Journal:  Hum Mol Genet       Date:  2015-06-30       Impact factor: 6.150

3.  Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.

Authors:  Cezary Cybulski; Dominika Wokołorczyk; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Bartłomiej Masojć; Tadeusz Deebniak; Bohdan Górski; Paweł Blecharz; Steven A Narod; Jan Lubiński
Journal:  J Clin Oncol       Date:  2011-08-29       Impact factor: 44.544

4.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

5.  Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.

Authors:  Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

6.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

7.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

8.  Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.

Authors:  Francisco Javier Gracia-Aznarez; Victoria Fernandez; Guillermo Pita; Paolo Peterlongo; Orlando Dominguez; Miguel de la Hoya; Mercedes Duran; Ana Osorio; Leticia Moreno; Anna Gonzalez-Neira; Juan Manuel Rosa-Rosa; Olga Sinilnikova; Sylvie Mazoyer; John Hopper; Conchi Lazaro; Melissa Southey; Fabrice Odefrey; Siranoush Manoukian; Irene Catucci; Trinidad Caldes; Henry T Lynch; Florentine S M Hilbers; Christi J van Asperen; Hans F A Vasen; David Goldgar; Paolo Radice; Peter Devilee; Javier Benitez
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

  8 in total
  40 in total

Review 1.  Germline Mutations in Triple-Negative Breast Cancer.

Authors:  Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2017-02-24       Impact factor: 2.860

Review 2.  Multifaceted Fanconi Anemia Signaling.

Authors:  Raymond Che; Jun Zhang; Manoj Nepal; Bing Han; Peiwen Fei
Journal:  Trends Genet       Date:  2017-12-16       Impact factor: 11.639

3.  Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.

Authors:  Muhammad Usman Rashid; Noor Muhammad; Umara Shehzad; Faiz Ali Khan; Asif Loya; Ute Hamann
Journal:  Fam Cancer       Date:  2022-07-08       Impact factor: 2.375

4.  Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.

Authors:  Takae Brewer; Lamis Yehia; Peter Bazeley; Charis Eng
Journal:  Am J Hum Genet       Date:  2022-08-04       Impact factor: 11.043

5.  Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia.

Authors:  Laura Kasak; Margus Punab; Liina Nagirnaja; Marina Grigorova; Ave Minajeva; Alexandra M Lopes; Anna Maria Punab; Kenneth I Aston; Filipa Carvalho; Eve Laasik; Lee B Smith; Donald F Conrad; Maris Laan
Journal:  Am J Hum Genet       Date:  2018-08-02       Impact factor: 11.025

6.  Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

Authors:  Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli
Journal:  JCO Precis Oncol       Date:  2019-09-17

7.  Expanding the spectrum of germline variants in cancer.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Sandeep Kumar Parvathareddy; Ismail A Al-Badawi; Nasser Al-Sanea; Luai H Ashari; Alaa Abduljabbar; Samar Alhomoud; Saif S Al-Sobhi; Asma Tulbah; Dahish Ajarim; Khalid Alzoman; Muna Aljuboury; Hussam Bin Yousef; Mohammed Al-Dawish; Fouad Al-Dayel; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Hum Genet       Date:  2017-10-03       Impact factor: 4.132

8.  Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.

Authors:  Irene Catucci; Ana Osorio; Brita Arver; Guido Neidhardt; Massimo Bogliolo; Federica Zanardi; Mirko Riboni; Simone Minardi; Roser Pujol; Jacopo Azzollini; Bernard Peissel; Siranoush Manoukian; Giovanna De Vecchi; Stefano Casola; Jan Hauke; Lisa Richters; Kerstin Rhiem; Rita K Schmutzler; Karin Wallander; Therese Törngren; Åke Borg; Paolo Radice; Jordi Surrallés; Eric Hahnen; Hans Ehrencrona; Anders Kvist; Javier Benitez; Paolo Peterlongo
Journal:  Genet Med       Date:  2017-08-24       Impact factor: 8.822

9.  Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex.

Authors:  Gustavo de Alencastro; Francesco Puzzo; Mara Pavel-Dinu; Feijie Zhang; Sirika Pillay; Karim Majzoub; Matthew Tiffany; Hagoon Jang; Adam Sheikali; M Kyle Cromer; Ruhikanta Meetei; Jan E Carette; Matthew H Porteus; Katja Pekrun; Mark A Kay
Journal:  Mol Ther       Date:  2020-10-22       Impact factor: 11.454

10.  Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes.

Authors:  Hafdis T Helgadottir; Jessada Thutkawkorapin; Kristina Lagerstedt-Robinson; Annika Lindblom
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.